Amgen Inc. (NASDAQ:AMGN) Shareholders to Get $2.52 Quarterly Dividend

Amgen Inc. (NASDAQ:AMGN) declared a quarterly dividend on Tuesday, October 27th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share by the medical research company on Friday, December 11th. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th.

Amgen has raised its dividend payment by an average of 0.1% per year over the last three years and has increased its dividend every year for the last 14 years. Amgen has a dividend payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Amgen to earn $24.61 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 41.0%.

Amgen Stock Up 0.7%

Shares of AMGN opened at $447.95 on Wednesday. The company has a 50-day simple moving average of $418.42 and a 200-day simple moving average of $372.80. Amgen has a 52 week low of $288.00 and a 52 week high of $450.98.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the previous year, the business posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts anticipate that Amgen will post 22.96 earnings per share for the current fiscal year.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported encouraging pipeline developments ahead of the American College of Rheumatology meeting. Phase 3 OASIZ-301 data for dazodalibep in Sjögren’s disease showed statistically significant and clinically meaningful improvements, while additional UPLIZNA, KRYSTEXXA and TAVNEOS data could support the company’s rare-disease growth strategy. Amgen ACR Convergence 2026 data
• Positive Sentiment: Amgen’s Imdelltra, combined with AstraZeneca’s Imfinzi, reportedly reduced the risk of death by 58% in a Phase 3 small-cell lung cancer study and extended median survival to 21.1 months, strengthening the outlook for the oncology portfolio. Amgen AstraZeneca lung cancer data
• Positive Sentiment: Goldman Sachs and TD Cowen maintained Buy recommendations on AMGN, signaling continued confidence in Amgen’s earnings and pipeline prospects. The company also declared a quarterly dividend of $2.52 per share, or $10.08 annualized, providing a yield of approximately 2.3%. Goldman Sachs Buy rating
• Neutral Sentiment: Jefferies raised its price target to $428 from $410, while Barclays increased its target to $400 from $380. Both targets remain below the stock’s recent trading level, suggesting analysts see improving fundamentals but potentially limited near-term valuation upside. Jefferies raises Amgen price target
• Neutral Sentiment: Amgen appointed former Cardinal Health CEO David W. Gibbs to its board. The addition brings healthcare leadership experience but is unlikely to materially change the investment thesis immediately. Amgen appoints David Gibbs
• Negative Sentiment: The FDA issued a warning concerning a promotional video for Amgen’s Vectibix cancer treatment, creating a compliance and reputational overhang. Investors are also awaiting the next earnings report, with one preview warning that current indicators do not strongly support an earnings beat. FDA warning over Vectibix promotional video

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.